64x Bio logo

64x Bio

Enabling next generation medicines. A comprehensive platform and…

Summer 2018Healthcare / Healthcare -> Industrial BioSan Francisco, CA, USA25 employees
Gene Therapy
Machine Learning

About

The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.

Founders (1)

Lexi Rovner
Co-founder & CEO

Details

Status
Active
Stage
Early
Team Size
25
Regions
United States of America, America / Canada